Scientific Due Diligence
Your success is our commitment.
Our passion for science is your advantage.
An independent technical view on small-molecule assets and programs, written for investment committees and BD teams.
Before a fund commits capital to a small-molecule biotech, someone has to read past the pitch deck and form a view on the actual science. I provide that view as an independent senior medicinal chemist with hands-on experience across the modalities most relevant to early-stage investing today.
Who is it for
This service is built for:
- Venture capital funds evaluating early-stage small-molecule biotech opportunities
- Family offices and angel investors backing scientific founders
- Corporate BD and licensing teams reviewing in-licensing or acquisition candidates
- Foundations and grant bodies that need independent expert review
If the science needs an external read before capital is committed, this is the service.
What you receive
A written report covering the scientific strength and weaknesses of the asset
- A written report covering the scientific strength and weaknesses of the asset
- A clear-eyed view of the chemistry, including hit and lead quality, selectivity, and stage-appropriate readiness
- An assessment of whether the proposed development timeline and budget hold up to scrutiny
- A risk summary covering scientific, execution, and where relevant IP-related concerns
- Specific, targeted questions to put to the management team in the next call
- A short executive summary suitable for investment committee circulation
- A follow-up call to walk through the findings and answer questions
Would you like to discuss how we can support your project?
Or would you like to become part of our scientific network as external partner?
Book a free consultation and explore if we are a good fit for each other